<DOC>
	<DOCNO>NCT00822770</DOCNO>
	<brief_summary>The goal clinical research study learn safety AMD3100 ( plerixafor ) G-CSF ( filgrastim ) combination fludarabine , busulfan , allogeneic blood stem cell transplant . This treatment study patient acute myeloblastic leukemia ( AML ) , myelodysplastic syndrome ( MDS ) , Chronic myelogenous leukemia ( CML ) .</brief_summary>
	<brief_title>Plerixafor Granulocyte Colony-stimulating Factor ( G-CSF ) With Busulfan , Fludarabine Thymoglobulin</brief_title>
	<detailed_description>The Study Treatment : Fludarabine chemotherapy drug design make cancer cell less able repair damage DNA ( genetic material cell ) . This may increase likelihood cell die . Busulfan chemotherapy drug design bind DNA , may cause cancer cell die . It commonly use stem cell transplant . Plerixafor filgrastim design cause cancer cell move bone marrow blood stream . This may help make cancer cell sensitive kill chemotherapy . An `` allogeneic '' ( donor ) stem cell transplant design help recipient 's body attack cancer cell may remain body chemotherapy . Study Groups Plerixafor Dose Levels : If find eligible take part study , assign study group base join study . Up 4 group 3 participant enrol Phase I portion study , 48 participant enrol Phase II . If enrolled Phase I portion , dose plerixafor receive depend join study . The first group participant receive low dose level plerixafor . Each new group receive high dose plerixafor group , intolerable side effect see . This continue high tolerable dose plerixafor find . If enrol Phase II , receive plerixafor high dose tolerate Phase I portion . In study , plerixafor study drug different dose level test compare . Drug Administration Before Transplant : You receive first dose filgrastim Day -9 . ( Day -9 mean 9 day stem cell transplant , occur Day 0 ) . Filgrastim injected skin day Day -9 Day -4 . Plerixafor injected skin day Day -7 Day -4 . The plerixafor injection occur 8 hour fludarabine busulfan chemotherapy . The fludarabine busulfan give vein central venous catheter ( CVC ) . A CVC sterile flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form procedure . Fludarabine give day Day -6 Day -3 , 1 hour time . On day , busulfan give fludarabine , 3 hour . You also receive tacrolimus order low risk graft vs. host disease ( GVHD ) . GVHD disease occur donor 's immune cell react recipient 's body , attack recipient 's cell tissue . Starting Day -2 , tacrolimus give continuous ( non-stop ) infusion CVC . When study doctor decide seem safe , begin take tacrolimus mouth instead , long study doctor decide necessary . If stem cell donor someone relate , receive antithymocyte globulin ( ATG ) CVC day Day -3 Day -1 . On Day -3 , give least 6 hour . On Days -2 -1 , give least 4 hour . This drug give order weaken immune system order low risk immune system reject transplanted cell . Blood Tests Before Transplant : If Phase I part study , follow blood sample draw optional . Eight total blood sample ( 1 1/2 teaspoon ) draw daily routine morning lab begin first dose study therapy ( Day -9 ) Day -3 . These sample use research purpose , study chemotherapy drug transplant may affect normal cell cancerous cell . If Phase II part study follow blood sample optional agree , eight total blood sample ( 1 1/2 teaspoon ) draw daily begin first dose study therapy ( Day -9 ) Day -3 . These sample use research purpose , study chemotherapy drug transplant may affect normal cell cancerous cell . Stem Cell Transplant : On Day 0 , 2 day rest chemotherapy , donor 's stem cell give vein ( CVC ) . This take 30-60 minute . Drug Administration After Transplant : In addition continue receive tacrolimus low risk GVHD ( describe ) , transplant also receive methotrexate low risk GVHD . Methotrexate give vein , CVC , 15 minute Days 1 , 3 , 6 . It also give Day 11 stem cell donor someone relate . Once day , start 1 week transplant , receive filgrastim injection skin . These daily injection continue blood count recover . Reasons Stopping Study Treatment Early : If experience intolerable side effect disease get bad study treatment , take study treatment . Other Procedures After Transplant : You remain hospital blood count recover ( usually 4 week transplant ) . You continue monitored infection transplant-related side effect least 100 day transplant . At 1 , 3 , 6 , 12 month transplant , blood test ( 3 tablespoon ) bone marrow biopsy perform check status disease . Length Study Participation : Your active participation study 12 month transplant . The study staff continue contact local doctor regularly . The purpose check status disease see . Up 72 patient take part study . All enrol The University Texas ( UT ) MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>1 . Patients age &gt; /=18 &lt; /= 65 year . 2 . Diagnosis AML first great remission , first subsequent relapse , primary induction failure ; MDS intermediate high risk International Prognostic Scoring System ( IPSS ) score fail respond recurred chemotherapy ; remission active disease treatment ; AML arise MDS ; CML fail respond imatinib tyrosine kinase inhibitor &gt; 5 % blast blood bone marrow . Patients receive second transplant relapse consider relapse group . 3 . White Blood Count ( CBC ) &lt; /= 20 * 10^9/l . 4 . Patients histocompatible , related unrelated volunteer donor available . A histocompatible donor define HLA match related donor unrelated donor match HLA A , B , C , DR antigens highresolution DNA technique . 5 . Zubrod performance status 0 1 , Karnofsky performance status 90100 % . 6 . Left ventricular ejection fraction &gt; /= 45 % . No uncontrolled arrhythmia uncontrolled symptomatic cardiac disease . 7 . No symptomatic pulmonary disease . Forced expiratory volume 1 ( FEV1 ) , force vital capacity ( FVC ) diffusion capacity carbon monoxide ( DLCO ) &gt; /= 50 % expect , correct hemoglobin . 8 . Serum creatinine &lt; /=1.5 mg/dl . 9 . Serum glutamic pyruvic transaminase ( SGPT ) &lt; /= 200 IU/ml unless related malignancy . 10 . Total serum bilirubin &lt; /=1.5 mg/dl ( unless Gilbert 's syndrome ) alkaline phosphatase &lt; /=2.5 time laboratory standard upper limit normal ( ULN ) . 11 . Patient patient 's legal representative able sign inform consent . 1 . History HIV positive . 2 . Positive Beta human chorionic gonadotropin ( HCG ) test woman child bear potential define postmenopausal 12 month previous surgical sterilization . 3 . Pleural/pericardial effusion ascites estimate &gt; /= 1 liter . 4 . Uncontrolled infection , respond appropriate antimicrobial agent seven day therapy . 5 . History acute hepatitis , chronic active hepatitis cirrhosis . 6 . Patients class 3 4 angina ( New York Heart Association ( NYHA ) criterion ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Blood Stem Cell Transplantation</keyword>
	<keyword>Bone Marrow Transplantation</keyword>
	<keyword>Bone Marrow Cell Transplantation</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Allogeneic Hematopoietic Transplantation</keyword>
	<keyword>Advanced Myeloid Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Graft Versus Host Disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>ATG</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex™</keyword>
	<keyword>Myleran®</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara™</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Plerixafor</keyword>
	<keyword>Antithymocyte globulin</keyword>
	<keyword>Thymoglobulin</keyword>
</DOC>